ISRCTN48489393已完成不适用
Heart protection study
Medical Research Council (MRC) (UK)0 个研究点目标入组 20,000 人开始时间: 2000年4月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients at high risk of CHD (e.g., because of history of vascular disease or diabetes)
- •2. Without clear indication for or contra-indication to statin
- •3. Male and female adults
- •4. Non-fasting blood total cholesterol concentrations of at least 3.5 mmol/L (135 mg/dL)
排除标准
- •1. The patient's doctor considered statin therapy to be clearly indicated or contra-indicated
- •2. A past history of: stroke, myocardial infarction or angina hospitalisation within the previous six months
- •3. Chronic liver disease or evidence of abnormal liver function
- •4. Severe renal disease or evidence of substantially impaired renal function
- •5. Inflammatory muscle disease or evidence of muscle problems
- •6. Concurrent treatment with cyclosporin, fibrates or high-dose niacin
- •7. Child-bearing potential
- •8. Severe heart failure
- •9. Life-threatening conditions other than vascular disease or diabetes (including any cancer except non-melanoma skin cancer)
- •10. Any other condition that might limit long-term compliance
研究者
相似试验
已完成
不适用
Remote ischaemic postconditioning in the clinical settingTopic: Cardiovascular, NeurologicalSubtopic: Cardiovascular (all Subtopics), Neurological (all Subtopics)Disease: Cardiovascular, Nervous system disordersCirculatory SystemMyocardial ischaemia-reperfusion injuryISRCTN78348355niversity College London (UCL) (UK)500
招募中
Unknown
Study on providing cardiovascular disease prevention services using telemonitoring with IoT medical devicesHeart failureJPRN-UMIN000051144General Incorporated Association telemedEASE10
进行中(未招募)
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-ROovo Nordisk A/S3,183
进行中(未招募)
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-ITOVO NORDISK. S.P.A.3,183
进行中(未招募)
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-GBovo Nordisk A/S3,183
